Pacira BioSciences' Accumulated Expenses rose 4.28% to $79.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.6 million, marking a year-over-year increase of 4.28%. This contributed to the annual value of $80.1 million for FY2024, which is 24.72% up from last year.
Pacira BioSciences' Accumulated Expenses amounted to $79.6 million in Q3 2025, which was up 12.14% from $71.0 million recorded in Q2 2025.
Pacira BioSciences' Accumulated Expenses' 5-year high stood at $127.6 million during Q4 2021, with a 5-year trough of $50.2 million in Q1 2021.
In the last 3 years, Pacira BioSciences' Accumulated Expenses had a median value of $66.8 million in 2024 and averaged $69.2 million.
In the last 5 years, Pacira BioSciences' Accumulated Expenses spiked by 79.72% in 2021 and then dropped by 29.70% in 2023.
Over the past 5 years, Pacira BioSciences' Accumulated Expenses (Quarterly) stood at $127.6 million in 2021, then declined by 29.61% to $89.8 million in 2022, then fell by 28.45% to $64.2 million in 2023, then climbed by 24.72% to $80.1 million in 2024, then grew by 4.28% to $79.6 million in 2025.
Its Accumulated Expenses stands at $79.6 million for Q3 2025, versus $71.0 million for Q2 2025 and $80.1 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value